Dimensional Fund Advisors LP Takes Position in Mineralys Therapeutics, Inc. (NASDAQ:MLYS)

Dimensional Fund Advisors LP purchased a new stake in Mineralys Therapeutics, Inc. (NASDAQ:MLYS - Free Report) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 16,412 shares of the company's stock, valued at approximately $202,000.

Other hedge funds have also made changes to their positions in the company. China Universal Asset Management Co. Ltd. boosted its stake in shares of Mineralys Therapeutics by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,553 shares of the company's stock valued at $130,000 after acquiring an additional 989 shares during the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Mineralys Therapeutics during the fourth quarter valued at $154,000. AlphaQuest LLC boosted its stake in shares of Mineralys Therapeutics by 2,637.8% during the fourth quarter. AlphaQuest LLC now owns 15,222 shares of the company's stock valued at $187,000 after acquiring an additional 14,666 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Mineralys Therapeutics by 119.0% during the fourth quarter. SG Americas Securities LLC now owns 19,961 shares of the company's stock valued at $246,000 after acquiring an additional 10,845 shares during the last quarter. Finally, Proficio Capital Partners LLC acquired a new stake in shares of Mineralys Therapeutics during the fourth quarter valued at $285,000. Hedge funds and other institutional investors own 84.46% of the company's stock.

Analysts Set New Price Targets

A number of analysts recently commented on the company. Wall Street Zen raised Mineralys Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday. The Goldman Sachs Group decreased their price objective on Mineralys Therapeutics from $28.00 to $24.00 and set a "buy" rating on the stock in a research note on Thursday, February 13th. Guggenheim set a $48.00 price objective on Mineralys Therapeutics and gave the company a "buy" rating in a research note on Wednesday, May 14th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $42.00 price objective on shares of Mineralys Therapeutics in a research note on Tuesday, May 13th.

Insiders Place Their Bets

In other news, insider David Malcom Rodman sold 11,366 shares of Mineralys Therapeutics stock in a transaction dated Wednesday, May 14th. The stock was sold at an average price of $15.29, for a total value of $173,786.14. Following the transaction, the insider now directly owns 106,669 shares of the company's stock, valued at $1,630,969.01. The trade was a 9.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CFO Adam Scott Levy sold 10,757 shares of Mineralys Therapeutics stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $12.06, for a total value of $129,729.42. Following the completion of the transaction, the chief financial officer now directly owns 215,340 shares in the company, valued at $2,597,000.40. This represents a 4.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 104,579 shares of company stock valued at $1,534,353. Insiders own 25.56% of the company's stock.

Mineralys Therapeutics Price Performance

NASDAQ:MLYS traded down $0.36 during mid-day trading on Friday, reaching $15.96. The company's stock had a trading volume of 927,902 shares, compared to its average volume of 485,593. The company's fifty day simple moving average is $14.49 and its two-hundred day simple moving average is $12.57. Mineralys Therapeutics, Inc. has a twelve month low of $8.24 and a twelve month high of $18.38. The stock has a market cap of $1.04 billion, a P/E ratio of -4.38 and a beta of -0.30.

Mineralys Therapeutics (NASDAQ:MLYS - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.79) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.02) by $0.23. Sell-side analysts expect that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Mineralys Therapeutics Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.